Bristol-Myers Squibb in new oncology collaboration
pharmafile | November 25, 2015 | News story | Research and Development | Bristol-Myers Squibb, collaboration, immuno-oncology, investment, venture capital
Bristol-Myers Squibb and European healthcare fund Life Sciences Partners are forming a strategic collaboration to identify breakthrough technologies.
The companies will work closely together to find breakthrough technologies and products in immuno-oncology and other areas of unmet medical need.
The collaboration is underpinned by a significant investment by Bristol-Myers Squibb in LSP 5, the latest LSP fund. This is the first investment by Bristol-Myers Squibb in a European healthcare fund. The advantage of the collaboration means there will be close interaction with BMS’ R&D staff, who will give expert input which will provide LSP a better understanding of what pharma companies want to see and acquire.
Immuno-oncology is one of the most dynamic areas in biotechnology, and Bristol-Myers Squibb is working to position itself as one of the leaders in this field – with several immuno-oncology products already on the market. The company is also pursuing potential treatment options in other areas of significant unmet need, including cardiovascular diseases such as heart failure and thrombosis, certain genetic diseases, fibrosis and immunoscience.
Paul Biondi, senior vice president of business development at Bristol-Myers Squibb, says: “We are committed to working closely with the venture community to identify and invest in innovative science that has the potential to bring forward transformational medicines to patients with unmet need.”
Dr Joachim Rothe, general partner at LSP, says: “LSP is committed to seeking, nurturing and growing healthcare investment opportunities which have the potential to have a positive impact on society.
We are very proud to be chosen by Bristol-Myers Squibb as a partner for investing in European innovation, which is validation of LSP´s influential role as a long-standing specialist European life science investor. We are excited to be working with Bristol-Myers Squibb and welcome Dr Donnie McGrath, vice president of business development at Bristol-Myers Squibb, to the LSP 5 advisory board. We have no doubt this will be a highly productive and complementary collaboration to promote innovation in European life sciences.”
Yasmita Kumar
Related Content
EVerZom enters research and licensing agreement with GENFIT
EVerZom, a French biotech company developing exosome-based therapies for regenerative medicine, has entered into a …
Custom Pharmaceuticals launches new company for drug product development
Customs Pharmaceuticals, a full-service contract development and manufacturing organisation (CDMO), has launched Centrix Pharma Solutions, …
Apiary invests in life sciences SEO pioneer PIO to support global expansion
Private equity firm Apiary Capital has invested in performance-io (PIO), a specialist life sciences performance …
